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Abstract
P-Element induced wimpy testis (PIWI)-interacting RNAs (piRNAs) are a type of noncoding RNAs 
(ncRNAs) and interact with PIWI proteins. piRNAs were primarily described in the germline, 
but emerging evidence revealed that piRNAs are expressed in a tissue-specific manner among 
multiple human somatic tissue types as well and play important roles in transposon silencing, 
epigenetic regulation, gene and protein regulation, genome rearrangement, spermatogenesis 
and germ stem-cell maintenance. PIWI proteins were first discovered in Drosophila and they 
play roles in spermatogenesis, germline stem-cell maintenance, self-renewal, retrotransposons 
silencing and the male germline mobility control. A growing number of studies have 
demonstrated that several piRNA and PIWI proteins are aberrantly expressed in various kinds 
of cancers and may probably serve as a novel biomarker and therapeutic target for cancer 
treatment. Nevertheless, their specific mechanisms and functions need further investigation. 
In this review, we discuss about the biogenesis, functions and the emerging role of piRNAs 
and PIWI proteins in cancer, providing novel insights into the possible applications of piRNAs 
and PIWI proteins in cancer diagnosis and clinical treatment.
IntroductionAlthough more than 70% of the human genome is actively transcribed, only 1~2% of the human genome are protein-coding genes, and the major group of transcripts are noncoding 
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RNAs (ncRNAs) [1]. ncRNA can be classified into two groups, including housekeeper ncRNAs and regulatory ncRNAs. Regulatory ncRNAs can be subdivided into small noncoding RNAs 
with transcripts shorter than 200 nucleotides and long noncoding RNAs (lncRNAs) with 
transcripts longer than 200 nucleotides. MicroRNAs (miRNAs), P-Element induced wimpy testis (PIWI) - interacting RNA (piRNAs), small interfering RNA (siRNAs) and small nucleolar RNA (snoRNA) all belong to small noncoding RNAs [2]. Among these regulatory small 
ncRNAs, miRNAs have been extensively studied, which can regulate gene expression via binding to the sequence of target mRNAs [3-5], while piRNAs are the newest type and are 
drawing increasing attention nowadays.As a class of noncoding small RNA of 24–32 nucleotides, piRNAs are primarily named “repeat associated small interfering RNAs (rasiRNAs)” [6, 7]. But because of their interaction 
with PIWI subfamily of Argonaute proteins, they were formally defined as piRNAs in mammalian systems in 2006 [8-12]. By binding to PIWI proteins to form a piRNA/ PIWI-complex, piRNAs exert a silencing effect in the PIWI-dependent transposon silencing, epigenetic regulation, gene and protein regulation, genome rearrangement, and germ stem-cell maintenance [13-15]. At the same time, piRNAs serve a pivotal role in reproduction 
and fertility regulation [16-19], which were accumulated at the onset of meiosis or during spermatogenesis [10, 11].
PIWI proteins were first discovered in Drosophila [20], in which they play roles in 
germline stem-cell maintenance and self-renewal [21]. Here, PIWIs refers collectively to 
PIWI proteins, while Piwi refers to the individual protein. There are three type of Argonaute 
proteins including Aub, Piwi and AGO3 (endonucleases) in the germline cells, belonging to 
the PIWI subfamily of proteins [22, 23]. As a nuclear protein, Piwi has important functions 
in retrotransposons silencing and the male germline mobility control [24]. In addition, Piwi 
is also involved in spermatogenesis [18]. Knockout mutations in Piwi proteins could result in defects in sperm development [24]. Recently, several studies have confirmed the function 
of piRNAs and PIWI proteins in cancer. However, there remain underlying functions and mechanisms of piRNAs and PIWI proteins requiring further elucidation.
In this review, we will first discuss about the biogenesis and functions of piRNAs. Then 
we talk about the piRNAs and PIWI proteins in cancer development, piRNA datasets as well as piRNA predictions, providing possible applications of piRNAs and PIWI proteins in cancer diagnosis and clinical treatment.
Biogenesis of piRNAsThere are mainly three groups of piRNAs according to multiple origins: transposon-derived 
piRNAs, mRNA-derived piRNAs and lncRNAs-derived piRNAs. As the only well understood type of piRNAs, transposon-derived piRNAs are transcribed from both genomic strands and produce both sense and antisense piRNAs; mRNA-derived piRNAs are processed and often originate from 3’ untranslated regions (UTRs); lncRNAs-derived piRNAs are produced from the entire transcript [26, 27]. Unlike stem-loop or double-stranded precursors of miRNAs and siRNAs that are processed by the RNAse III Dicer, piRNAs are mostly transcribed as 
large (up to 200 kb) single-stranded precursors, which are processed independently from 
Dicer ribonuclease [28-30]. There are no significant secondary structures of the stem-loop 
structures in piRNAs precursors detected in regions surrounding piRNAs which is different 
from miRNAs [31-33]. And piRNAs also don’t show any phasing within a cluster sequence 
or overlap with each other like siRNAs [34]. Nevertheless, precursors of piRNAs also require 
further post transcriptional processing to become fully matured like other well investigated small regulatory ncRNAs.
There are mainly two mechanisms to generate mature piRNAs after transcription (Fig. 
1): the primary synthesis mechanism and the ‘ping-pong’ amplification mechanism [27]. 
The primary transcript is first cleaved by the riboendonuclease Zucchini in the simplest scenario in Drosophila gonad somatic cells. The 3’fragment is incorporated in PIWI proteins 
and trimmed to a final length by a 3’ to 5’ exonuclease. The 2’ hydroxy group at the 3’ end is 
methylated by the enzyme Hen1 while the 5’end residue of the piRNA incorporated in PIWI 
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Fig. 1. Biogenesis of piR-
NAs. There are mainly two mechanisms: the primary synthesis mechanism and the ‘ping-pong’ am-
plification mechanism to generating mature piR-NAs after transcription. 
In the primary pathway, the primary transcript is 
first cleaved by the ribo-
endonuclease Zucchini in the simplest scenario. The 3’fragment is incorporat-ed in PIWI proteins and 
trimmed to a final length by a 3’ to 5’ exonuclease. The 2’ hydroxy group at the 3’ end is methyl-
ated by the enzyme Hen1 
while the 5’end residue of the piRNA incorporated in 
PIWI shows a strong favoring for uridine residues. After processed into final length, the piRNAs bind PIWI 
proteins respectively to form a piRNA/PIWI complex and migrate back to the nucleus. In the secondary 
pathway, piRNAs form piRNA/AGO or piRNA/AUB complexes, which contain complementary sequences and provide substrate to each other.
shows a strong bias for uridine residues. After processed into final length, the piRNAs bind PIWI proteins respectively to form a piRNA/PIWI complex [14]. Then the complex migrates 
back to the nucleus and reaches its target gene to mobilize silencer machinery to further 
block the transcription of that target gene through complementary base pairing of piRNAs 
and DNA. In this way, piRNAs are transcriptional regulators that act mainly on transposable 
element (TE) sequences by recruiting histone methyltransferases, which will lead to the establishment of transcriptionally silent heterochromatin [34].
After generating a primary piRNA, piRNA’s accumulation needs amplification by the 
‘ping–pong’ mechanism which occurs in the cytoplasm [14]. Different from the primary 
synthesis that associates with PIWI proteins, piRNAs join with AGO3 or AUB proteins to 
form piRNA/Ago or piRNA/Aub complexes, which contain complementary sequences to 
each other. piRNA/Ago complex can produce a sequence of RNA that will serve as a substrate 
for the formation of a new piRNA which is capable to load an Aub protein. Then the resulting 
piRNA/Aub protein complex will produce additional RNA substrates which form new 
piRNA/Ago3 complex in the same way. In other word, the products of piRNA in the cytoplasm 
provide substrate for another functional piRNA molecule, which is based on an amplification 
mechanism [35]. Ping–pong signatures have been identified in zebrafish, D. melanogaster 
and very primitive animals like sponges, indicating the ‘ping–pong’ cycle may exist in early 
evolutionary stage [36]. However, previous evidence showed that piRNAs biogenesis during adult spermatogenesis in mice is independent of the ‘ping–pong’ mechanism [37]. In 
mammals, piRNA/PIWI mechanisms show a diversity, which needs further exploration.
Functions of piRNAs
Actually, it is quite difficult to establish the functionality of piRNAs because of the wide 
variation in piRNA sequences and functions over species [38]. Up to now, piRNAs have been implicated in transposon silencing, epigenetic regulation, gene and protein regulation, 
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genome rearrangement, spermatogenesis and germ stem-cell maintenance. Nevertheless, it 
still requires great endeavor to elucidate the specific functionalities of piRNAs.
Transposons silencingpiRNA has a role in RNA silencing via the formation of an RNA-induced silencing complex (RISC). It can direct the PIWI proteins to their transposon targets by binding to PIWI proteins [39]. A decreased or absent gene expression of PIWI lead to an increased 
expression of transposons [39]. Transposable elements (TEs) can be grouped into two types 
according to their mode of replication: 1) retrotransposons, which are transcribed into RNA 
intermediates; 2) DNA transposons, which do not need transcription to be mobilized [40]. TEs are found to have a high potential to cause deleterious effect on their host [41], contributing to genetic diversity and genetic instability [42, 43] and further leading to pathogenesis 
through gene deregulation, deleterious mutation and chromosome rearrangement as well as cancers [44]. The non-long terminal repeat (non-LTR) TEs can be classified into long interspersed elements (LINEs) and short interspersed elements (SINEs). non-LTR families 
L1, SVA, and Alu have been implicated in breast, colon, ovarian cancers and leukemia [45]. 
For instance, it has been proved that both in vivo and in vitro L1 insertions are involved in a diversity of cancer types [46]. The PIWI establishes a repressive chromatin state by 
increasing the trimethylation of the lysine-9 residue of histone-3 (H3K9me3) and HP1 
chromatin marks at the transcriptional level [47]. Loss of piRNA has been linked to the loss 
of histone H3K9me3 and an increase in POL II occupancy at TEs [47]. And it has also been 
demonstrated that the recruitment of the heterochromatin protein HP1 to a piRNA reporter 
subject to transcriptional gene silencing (TGS) [47]. Then piRNA/PIWI complex recruits 
epigenetic factor HP1a and then HP1 recruit the histone methyltransferase Su(var)3-9 to 
the place that is responsible for most H3K9 methylation in Drosophila to exert functions 
[48] (Fig. 2). In the somatic tissues of developing embryos, retrotransposon Tirant initiated 
H3K9-mediated transcriptional gene silencing were against by maternally deposited piRNAs in Drosophila simulans [49]. Interestingly, a study found that genes containing or 
in proximity to TE sequences may be piRNA pathway targets. TE sequences are targeted by 
Piwi for silencing and transcriptional repression was closely related with the presence of a transposon or its remnants in an intron or in proximity to a gene [50, 51]. These findings 
present us a Piwi-mediated TGS model where Piwi translocates to the nucleus to interact 
with nascent transcript or DNA at the target locus potentially, which in turn results in 
heterochromatin formation and transcriptional repression. Moreover, final silencing mark may not be the histone methylation. Current studies indicated that the high mobility group 
protein Maelstrom may act downstream of Piwi and histone methylation [50]. However, the exact role of Mael remains to be investigated.
In mammals, it has been demonstrated that the PIWI-like proteins Miwi2 is similar to the PIWI protein present in Drosophila [22] and both Mili and Miwi2 have an effect on the repetitive elements methylation and stable transposons repression maintenance in mice [13, 22]. Furthermore, a decreased expression of piRNA cluster was correlated to an increase of TE activity [52]. Transposons silencing of piRNAs by DNA methylation could 
lead to transcriptional gene silencing. For instance, in the central nervous system (CNS) and other somatic tissues in Aplysia, piRNAs could induce CpG methylation and transcriptional 
silencing of a key plasticity related gene, CREB2 [53].
Epigenetic activator
In addition to take part in transposon silencing, a growing body of evidence indicates 
that Piwi can also serve as an epigenetic activator. In Drosophila, Piwi regulates chromosome 3R telomere-associated sequence (3R-TAS) positively and the absence of PIWI has an 
opposite genomic regulatory effects on different parts of the gene. For example, the absence 
of PIWI lead to enhanced telomere position effects in the white eye gene in Drosophila [54]. 
Piwi is need for the expression of 3R-TAS in a dose-dependent manner and can promote the 
active epigenetic state of 3R-TAS, implying an epigenetic activator role of Piwi [54]. However, 
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whether Piwi-binding lead to transcriptional silencing or activation may be correlated 
with what elements Piwi interacts with and/or is influenced by the local chromatin micro-
environment or its sublocalization within the nucleus. The potential mechanisms need further exploration.
Gene and protein regulators
piRNA can also act as host gene and protein regulator. For example, piR_015520 is in 
intron 1 of the human melatonin receptor 1A gene (MTNR1A) gene, which has an altered 
expression in prostate cancer cells. piR_015520 has been shown negatively regulated 
MTNR1A gene expression by binding to its genomic region and overexpression of piR_015520 lead to a repression of MTNR1A expression in a concentration-dependent manner [53]. 
This data manifests that piRNA expression level alterations could influence the expression 
level of the gene where the piRNA is located, providing a novel insight of piRNAs as gene regulators in humans.
Analogically, piRNAs also regulate its interacting proteins stability by binding to it. For 
instance, piRNAs regulated Piwi protein Miwi ubiqutination by enhancing Miwi interaction 
with an APC/C substrate-binding subunit during late mouse spermatogenesis [17]. Mei et 
al. [55] identified 555 piRNAs in human lung bronchial epithelial (HBE) and non-small cell 
lung cancer (NSCLC) cell lines. The results indicated that 295 piRNAs were novel piRNA-
like sncRNAs or piRNA-Ls. They found that piRNA/piRNA-L expressed aberrantly between 
HBE and NSCLC cells and among which piRNA-like-163 (piR-L-163) located in intron 10 
of the LAMC2 gene is the most down-regulated. Further, they found that piR-L-163 binds directly to phosphorylated ERM proteins (p-ERM). The ERM proteins (ezrin, radixin and moesin) belong to a family of proteins located at cell cortex and they play critical role in 
regulating signal transduction pathways by connecting transmembrane proteins [56, 57]. 
The piR-L-163/p-ERM interaction is critical for p-ERM’s binding capability to filamentous 
actin (F-actin) and ERM-binding phosphoprotein 50 (EBP50). These data demonstrated that 
piRNA/piRNA-L may interact directly with proteins in physiological and pathophysiological conditions. Lee et al. [58] recently discovered the direct molecular interaction of 
piRNA-36026 with target geneserpin peptidase inhibitor, clade A, member 1 (SERPINA1) 
or lecithin retinol acyltransferase (LRAT), which are two tumor suppressor proteins and subsequent molecular therapeutic responses including caspase-3 and phosphatidyl inositol (PI) in the nucleus by using a piR-36026 molecular beacon (MB).
Fig. 2. Epigenetic regulation of 
piRNA/Piwi pathway. A) In hetero-chromatin, piRNA/PIWI complex 
recruits epigenetic factor HP1a 
and then HP1 recruit the histone methyltransferase Su(var)3-9 to the place that is responsible for 
most H3K9 methylation to exert functions. Then Pol II transcription 
is inhibited and Piwi–piRNA target is silenced effectively by a critical 
mass of the H3K9 repressive chro-
matin marks through an unknown mechanism. B) In euchromatin, 
there are mainly two mechanisms. 
Piwi may first recruit the Su(var)3-
9and then HP1a bind the methylated H3K9. The other way is that Piwi may first recruit HP1a, and then HP1a 
recruits Su(var)3-9 which deposits methyl groups on the unmethylated H3K9. Both working models have inhibitory effect on RNA Pol II transcription.
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Other functions
piRNAs are also involved in genome rearrangement. Genome rearrangement is 
also called somatic elimination. It is known as a process that the zygotic genome in each 
daughter cell is extensively edited to create a new and partial somatic genome that replaces the parental germline genome to prevent their transcription in the resultant macronuclei 
when conjugated [59]. For instance, Piwi orthologues are essential for proper genome rearrangement and piRNA production in the ciliate Tetrahymena. After mating, long non-coding RNAs transcribed from the parental somatic macronucleus act as sponges for 
germline-derived piRNAs. Thus, unbound piRNAs specifically mark any non-somatic regions in the genome for elimination in developing daughter macronucleus [60]. The genome rearrangement in ciliate Oxytricha is different from the ciliate Tetrahymena. Injection of RNAs that target normally deleted genes leads to their retention through multiple sexual 
generations, demonstrating that piRNAs are as powerful as trans-generational carriers of 
epigenetic information for genome programming [61]. Taken together, in Tetrahymena, the 
minority of the developing somatic genome is directed for deletion, whereas in Oxytricha the minority of the developing somatic genome is directed for retention.
In addition, the piRNA/PIWI pathway also has a direct role in buffering against 
phenotypic variation. It has been confirmed that Piwi depletion in Drosophila can lead to 
new somatic defects in a random fashion and at low frequency. It is already an agreement 
that the heat-shock protein Hsp90 is a key chaperone in suppressing phenotypic variation, 
depletion of which could generate various somatic phenotypic variants in species ranging from Arabidopsis [62] to Drosophila [63]. Drosophila Piwi forms a complex with Hsp90 
and the heat-shock organizing protein, Hop, in vivo to serve as a phenotypic variation 
suppressor [64]. Furthermore, piRNAs also have functions in spermatogenesis, germ stem 
cell maintenance, etc. In murine spermatogenesis, it is observed that after the first stage 
of TE-derived piRNA production, in late stages of spermatogenesis piRNA recruit Miwi 
and deadenylase CAF1, a piRNA-induced silencing complex to assemble and induce mRNA 
deadenylation and degradation [65]. Clearly, Piwi has diverse roles in a variety of cellular processes, and it is challenging to further explore its potential functions. But it is believed 
that specific functions of piRNAs will be disclosed to improve our understanding on piRNAs in the near future.
piRNAs in cancerDifferent from miRNAs, most piRNAs are not complementary to the mRNA of potential target genes, indicating that piRNAs may be involved in epigenetic regulation instead of post-transcriptional regulation for controlling diverse biologic phenomena, including cancer [66, 67]. Epigenetic global alterations of cancers include DNA hypomethylation, histones 
hypoacetylation and gene-specific DNA hypermethylation, which results in oncogene activation (R-ras, cyclin D2) [68, 69] and tumor suppressor silencing (RB1, p16) [70]. 
Take a specific cell for example, only a restricted set of genes is active and is epigenetically 
regulated by a few piRNAs [65, 71], allowing a definition of unique tissue signatures, which 
is based on the profile of piRNAs expressed in a given tissue. In cancer tissues, aberrant expression of piRNAs implied by global hypomethylation and focal hypermethylation are 
probably potential cancer-specific signatures [72, 73]. Accumulating evidence has revealed that several piRNAs have been implicated in cancer development, though only a small number of piRNAs have been found to express in somatic tissues at present [74]. Martinez et al. [74] analyzed 6, 260 human piRNA transcriptomes derived from non-malignant and 
tumor tissues from 11 organs and discovered that only 273 of the 20, 831 known piRNAs are expressed in somatic non-malignant tissues and 522 piRNAs are expressed in corresponding 
tumor tissues, with a cancer-type specific manner. Altogether, piRNAs are involved in cancer cell proliferation, apoptosis, metastasis, invasion, and may be as potential prognostic and 
diagnostic biomarkers during cancer development (Table 1).
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piRNAs are involved in cancer cell proliferation and apoptosis
Hashim et al. [75] identified more than 100 piRNAs expressed in breast cancer by analyzing smallRNA-Seq data generated from breast cancer cell lines and tumor biopsies, 
some of which were influenced by cell cycle progression and the oncosuppressive estrogen 
receptor β (ERβ). piR-34736, piR-36249, piR-35407, piR-36318 and piR-34377 were 
significantly down-regulated while piR-36743, piR-36026 and piR-31106 were dramatically 
up-regulated among 100 identified piRNAs. Further evidence suggested that piRNAs do exert transcriptional and post-transcriptional gene regulatory actions in cancer cells. In addition, 
most piRNAs are sensitive to estrogen and estrogen deficiency can lead to piRNA expression 
level alterations. As a novel type of estrogen receptor, ERβ can control the metastasis of cancer cells, directly regulating piRNA expression in breast cancer and responding to stimulations 
inside and outside cancer cells. Therefore, the estrogen deficiency and the effect of ERβ on 
piRNA can both inhibit the breast cancer cells growth. Chu et al [76]. used piRNA microarrays to investigate global piRNA expression in three bladder cancer tissues and their adjacent 
normal tissues. They found that the expression levels of 106 piRNAs were up-regulated 
and 91 were down-regulated in bladder cancer tissues, among which piRNA DQ594040 
associated with bladder cancer (piRABC) is the most down-regulated. Over-expression of piRABC can inhibit bladder cancer cell proliferation, colony formation, and promote cell 
apoptosis though the up-regulation of TNFSF4 protein. piR-823 was found to be up-regulated 
in multiple myeloma (MM) patients and MM cell lines. PiR-823 was positively correlated with 
Table 1. Summary of cancer-associated piRNAs
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clinical stage, contrary to gastric cancer in which piR-823 was down-regulated. Silencing piRNA-823 in MM cells induced deregulation of cell cycle regulators and apoptosis-related proteins expression, and consequent tumorigenicity inhibition in vitro and in vivo. Moreover, 
piRNA-823 was directly related to de novo DNA methyltransferases, DNMT3A and 3B, in primary CD138+ MM cells. The inhibited expression of piRNA-823 in MM cells significantly 
reduced DNMT3A and 3B at both mRNA and protein levels, which in turn led to decrease in global DNA methylation and reexpression of methylation-silenced tumor suppressor, p16INK4A. In addition, piRNA-823 abrogation in MM cells reduced vascular endothelial growth factor secretion, accompanied by decreased proangiogenic activity, suggesting an oncogenic role of piRNA-823 in the biology of MM [77]. Jacobs et al. [78] utilized directly measured 
and imputed genotypes from the GliomaScan genome-wide association study (GWAS) to 
analyze piRNAs associated with glioma risk and the results revealed that piR-598 impacted 
cell survival and reduced glioma cell viability and colony formation, which sharply promoted 
cell proliferation. Recently, piR-55490 was found to be silenced in lung carcinoma specimens 
and cell lines, compared with normal lung tissues and cells, and piR-55490 suppression 
led to the gain in the proliferation rate. Further study revealed that piR-55490 suppressed 
the activation of Akt/mTOR pathway by binding 3’UTR of mTOR messenger RNA (mRNA) and induce its degradation in a mechanism similar to miRNA in lung cancer cells [79]. These results facilitate our understanding of piRNA’s functions and its role in cancer cell proliferation and apoptosis.
piRNAs are involved in cancer cell metastasis and invasion
To screen out differentially expressed piRNAs, deep sequencing was carried out in four breast cancer tissues and four matched non-tumor tissues. Then 4 piRNAs (piR-4987, piR-
20365, piR-20485 and piR-20582) were confirmed to be up-regulated by realtime RT-PCR in 
50 breast cancer (P < 0.001). Among them, piR-4987 up-regulation was positively associated 
with lymph node metastasis [80]. Another study showed that piR-932/PIWIL2 complex may positively regulate the process of breast cancer stem cells through promoting the methylation 
of Latexin, which in turn promotes epithelial-mesenchymal transition (EMT). Both piR-932 
and PIWIL2 could be potential targets for blocking the metastasis of breast cancer [81]. 
By deep sequencing 24 frozen benign kidney and clear cell renal cell carcinoma (ccRCC) specimens and using the publically available piRNA database, Li et al. [82] found 19 piRNAs 
were differentially expressed between ccRCC and benign kidney tissue, and 46 piRNAs were 
associated with metastasis. Among these metastasis-related piRNAs, they found piR-32051, 
piR-39894 and piR-43607 were derived from the same piRNA cluster at chromosome 17, and 
were overexpressed in embryonic and neoplastic kidney cell lines compared to benign as well. 
Further studies showed that these three aberrantly expressed piRNAs were validated to be 
highly associated with ccRCC metastasis, late clinical stage and poor cancer-specific survival. 
Analogically, Fu et al. [83] found that piR-021285 is involved in methylation at a number of 
known breast cancer-related genes including attenuated 5’ untranslated region (UTR)/first 
exon methylation at the proinvasive ARHGAP11A gene. Further studies revealed that both 
ARHGAP11A mRNA expression and invasiveness were concurrently increased in an in vitro cell line model. Cui et al. [84] observed that the levels of piR-823 in peripheral blood from 
patients with gastric cancer were remarkably lower than those in healthy controls and the 
expression level of piR-823 were positively associated with tumor-node-metastasis stage and 
distant metastasis, suggesting piRNAs may be valuable biomarkers for detecting circulating gastric cancer cells. Subsequently, Cheng et al. [85] found that overexpression of piR-823 
could inhibited cancer cell growth. Further, xenograft nude mice model confirmed its tumor suppressive role in a dose-dependent manner, indicating that piR-823 play a crucial role in 
gastric cancer. Recently, Iliev et al. demonstrated that piR-823 is down-regulated in tumor 
tissue, blood serum and urine of renal cell carcinoma (RCC) [86]. Law et al. [87] identified 
a novel piR-Hep1 which is up-regulated in hepatocellular carcinoma (HCC) compared to 
adjacent non-malignant liver tissues through deep sequencing. PIWIL2 expression was 
positively correlated with the expression of piR-Hep1 in HCC, suggesting the oncogenic 
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role piR-Hep1/PIWIL2 complexes. Silencing of piR-Hep1 inhibited cell viability, motility, 
and invasiveness, with a concomitant reduction in the level of active AKT phosphorylation, 
providing new insights into HCC tumorogenesis Therefore, piRNAs may play a key role in cancer cell metastasis and invasion, leading to cancer-related dysregulation.
piRNAs as diagnostic and prognostic biomarkers
Cheng et al. [88] used piRNA microarray to identify that piR-651 was significantly 
overexpressed in gastric cancer and then confirmed by PCR in a larger cohort of tumour 
and non-malignant tissues. The growth of gastric cancer cells was inhibited by a piR-651 
inhibitor and arrested at the G2/M phase in a dose dependent manner, suggesting piR-651 
may act as a potential marker for gastric cancer diagnosis. In addition, piR-651 was also 
confirmed to be up-regulated in other cancers including lung, colon, breast cancer tissues 
compared to paired noncancerous tissues. Busch et al. [89] identified 235 up-regulated 
and 369 down-regulated piRNAs in malignant tissue by piRNA microarray from 106 clear 
cell renal cell carcinomas patient samples. RT-qPCR analysis confirmed that piR-57125 was 
down-regulated in metastatic tumors while piR-30924 and piR-38756 were up-regulated 
in metastatic tumors. Furthermore, multivariate cox regression analyses revealed both piR-30924 and piR-57125 could be regarded as independent prognostic predictors, especially in non-metastatic patients. More recently, Martinez et al. [90] analyzed the transcriptomes of 358 non-malignant stomach tissue and gastric adenocarcinoma samples, founding that 
nearly half of the expressed piRNAs were overexpressed in tumors, including piR-59056, 
piR-32105, and piR-58099, which was capable to separate patients by risk of recurrence 
effectively. Similarly, the association between piR59056, piR-54878, and piR-62701 and 
recurrence-free survival was also observed in colon cancer. Chu et al. [91] observed that 
mRNA expression levels of LNC00964-3 which is an lncRNA that included the piR-015551 
sequence were significantly lower in colorectal cancer (CRC) tissues than in corresponding 
normal tissues. The expression of piR-015551 was positively correlated with the LNC00964-3 expression levels, indicating that piR-015551 may be possibly generated from LNC00964-
3, which may be involved in the development of CRC. piR-017061, located within HBII-296A 
snoRNA, revealed to be dramatically down-regulated in pancreatic ductal adenocarcinoma (PDAC) compared to nonmalignant pancreatic control tissues [92]. Currently, Krishnan et 
al. [93] discovered eight piRNAs as novel independent prognostic markers in breast cancer 
and their association with overall survival (OS) was confirmed in The Cancer Genome Atlas 
(TCGA) dataset. TCGA applies high-throughput genome analysis techniques to make us better understand the genetic bases of cancer [94]. The data showed that there are several piRNAs 
expressed in a cancer-related manner, offering evidence for the significance of piRNAs in diagnostic and clinical treatment. More importantly, piRNAs have an advantage of being short fragment, only 24–32 nt in length. This characteristic provides piRNAs an opportunity 
to pass through cell membrane easily instead of being degraded like other long RNAs and 
makes it detectable in patient samples like blood plasma and serum, saliva, sputum, and 
urine. A recent study found that piRNAs possess higher sensitivity and specificity compared 
to an existing miRNA-based biomarker detection system in gastric cancer [84]. Therefore, piRNAs are increasingly investigated to improve our understanding on the diagnosis of human cancers. Altogether, aberrantly expressed piRNAs in human cancers can be employed 
as a new class of diagnostic and prognostic biomarkers. There is an urgent need to shed light 
on the relationship between piRNAs and cancers in this promising field.
PIWI proteins in cancerIn addition to a role in cancer of piRNAs, PIWI proteins also play critical functions in 
tumorigenesis. There are four expressed PIWI proteins in humans: PIWIL1/HIWI, PIWIL2/
HILI, PIWIL3 and PIWIL4/HIWI2 [95]. Various studies have demonstrated that PIWI proteins are involved in cancer cell proliferation, apoptosis, metastasis, invasion and act as potential 
cancer diagnostic and prognostic biomarkers (Table 2).
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PIWI proteins are involved in cancer cell proliferation and apoptosis
It was first reported that HIWI was significantly overexpressed in seminoma, a testicular germ-cell tumor [96]. Consequent studies found that in gastric cancer, the progressively 
increased expression of HIWI from preneoplastic lesions to advanced cancer suggests that 
HIWI was associated with the proliferation of gastric cancer cells [97]. Cellular differentiation 
was inhibited when HIWI was increased in sarcoma precursors and the growth was 
inhibited when HIWI was down-regulated. HIWI could decrease cellular differentiation state 
to keep indefinite proliferation and could inversely correlate with tumor suppressor genes 
(TSGs), such as p15, p21 and p27. Further studies showed that HIWI-associated DNA hyper-
methylation with subsequent genetic and epigenetic changes favoring a tumorigenic state 
[98]. In addition, HIWI gene was found to be highly expressed in the lung cancer stem cell 
population SSCloAldebr cells. Knockdown of HIWI gene remarkably impaired the sphere 
Table 2. Summary of cancer-associated PIWI proteins
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formation ability and colony forming capacity of SSCloAldebr cells, further suppressing the 
tumor growth of SSCloAldebr cells in nude mice [99]. The promoting roles of HIWI proteins 
in cell proliferation were also demonstrated in breast cancer [100]. In glioma, Wang et al. 
[101] found that silencing HIWI could inhibit cell proliferation by promoting apoptosis 
and increase cell cycle arrest, influencing the expression of apoptosis and cell cycle related 
proteins, including p21, cyclin D1, Bcl-2, and Bax. Furthermore, in hepatocellular carcinoma 
cell lines, Hiwi was found to be down-regulated, leading to reduction of proliferation and migration of these cells, indicating an oncogenic role in hepatocellular carcinoma [102]. Taubert et al. [103] demonstrated that PIWIL2 silencing could dramatically reduce tumor cell proliferation, colony formation but increase apoptosis in vitro, inhibiting tumor growth. 
Further, it was demonstrated that the effect of PIWIL2 on tumorgenesis is through the 
Stat3/Bcl-XL pathway [104]. Moreover, it is indicated that PIWIL2 could directly bind to 
STAT3 protein via its PAZ domain and form a PIWIL2/STAT3/c-Src triple protein–protein 
complex. Then STAT3 was phosphorylated by c-Src and translocated to nucleus, binding p53 promoter and repressing its transcription to reduce apoptosis in tumor cells [105]. As a 
splice isoform of PIWIL2, PIWIL2-like (PL2L) protein PL2L60 is mainly expressed in diverse 
kinds of human and mouse tumor cells. It was found that PL2L60 could take part in cell-cycle 
progression by promoting the G0/1 to S phase transition and further to promote tumor cell 
survival and proliferation by up-regulating the nuclear expression of NF-κB, STAT3 and Bcl-2 [106]. PIWIL4 was also reported to play an oncogenic role in cervical cancer via impairing 
apoptosis through the p14ARF/p53 pathway to induce H3K9 methylation at the p14ARF 
locus without affecting the cell cycle in HeLa cells [107, 108]. All these findings present us an important role of PIWI proteins in cancer cell proliferation and apoptosis.
PIWI proteins are involved in cancer cell metastasis and invasion
PIWIL1 had a repressive effect on cell invasiveness in epithelial ovarian cancer (EOC) 
[109]. Knockdown of HIWI was found to inhibit the migration and invasion of glioma cells by 
reducing the expression of MMP-2 and MMP 9, indicating HIWI is an oncogene involved in 
the progression of glioma [101]. On the contrary, PIWIL1 expression increased in metastasis-
dependent manner in hepatocellular carcinoma (HCC) [97]. PIWIL2 was detected in various 
stages of human cervical squamous cell carcinomas (CSCC) and atypical glandular cells (AGC), 
low-grade and high-grade squamous intraepithelial lesions, and have the potential to be used 
as a complementary marker for p16 (INK4a) [110]. Additionally, Li et al. [111] observed 
that PIWIL2 expressed higher in primary colon cancer tissue and colon cancer tissue with 
lymph node metastasis compared with normal colon mucosa. Higher expression of PIWIL2 
was identified to be closely related to more aggressive clinical and pathological parameters, 
including five-year metastasis-free survival and overall survival. PIWIL2 knockdown also attenuated migration and invasion of colon cancer cells, regulating MMP9 transcriptional 
activities which can enhance migration and invasion of cancer cells [112]. Another study 
demonstrated that PIWIL2 was overexpressed significantly in breast cancer stem cells, 
and was associated with age, tumor size, histological type, tumor stage, and lymph node 
metastasis [81]. Moreover, PIWIL2 up-regulates RhoA, which in turn induces filamentary 
F-actin in a c-Myc-mediated manner. PIWIL4 can also promote cervical cancer cell invasion 
via down-regulating the expression of p14ARF and p53 [108]. Taking this evidence together, PIWI proteins are involved in cancer cell metastasis and invasion in tumorogenesis but 
specific mechanisms needs further investigation.
PIWI proteins as diagnostic and prognostic biomarkers
HIWI expression could be regarded as a potential biomarker for pathological diagnosis 
and prognosis for malignant gliomas and hepatocellular carcinoma (HCC) [112, 113]. And 
it was also related to poor prognosis, with a poor 5-year survival of gastric cancer patients 
[114]. It has been identified that HIWI led to poor outcomes in colon adenocarcinoma 
patients without lymph node metastasis [115]. On the contrary, the expression of HILI mRNA 
was lower in colorectal cancer tissues compared to corresponding non-cancerous samples, 
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indicating a reciprocal regulation between HIWI, HILI in colorectal cancer [116]. HILI is found to be expressed in breast cancer, colon cancer, gastrointestinal stromal tumors, renal 
cell carcinoma and endometrial carcinoma [104]. It was significantly related to histological grade, clinical stage and poorer clinical outcomes in esophageal cancer cells [117]. In 
addition, HILI was reported to be enriched in a cancer cell subpopulation expressing the 
stemness factors OCT4 and NANOG, consistent with the notion that PIWIs has a role in 
stem-cell maintenance and self-renewal [118]. Both PIWIL1 and PIWIL2 predicted poorer 
overall survival in gastric cancer tissue and PIWIL1 has been identified as an independent 
prognostic factor in gastric cancer [114]. PIWIL1 has been well demonstrated to mediate 
cancer development correlated with DNA hypermethylation. Chen et al. [119] found that 
PIWIL1 could promote the loss of PTEN expression which is an important tumor suppressor, 
and increase aberrant hypermethylation of PTEN gene promoter in Ishikawa cells through DNA methyltransferase 1 (DNMT1)-mediated PTEN hypermethylation in endometrial 
cancer. PIWIL2 expression was positively associated with colorectal cancer and was related to various clinic-pathologic parameters and a poor prognosis [120]. PIWIL2 showed different expression patterns in different stages of breast cancers. In both invasive and metastatic breast cancers, the cytoplasm, nucleus or both cytoplasm and nucleus, the expression of 
PIWIL2 can be observed but in breast pre-cancers, there are few PIWIL2 expressions in 
the nucleus, suggesting that PIWIL2 is likely to serve as a novel biomarker [121]. Yao et 
al. [122] showed that PIWIL2 can up-regulate c-Myc which serves as a crucial regulator in proliferation, invasion and metastasis among various human tumors via facilitating NME/
NM23 nucleoside diphosphate kinase 2 (NME2) to bind to G4-motif region within c-Myc 
promoter. Zeng et al. [123] indicated that the nuclear co-expression of Piwil2/Piwil4 had 
a worse prognostic phenotype in hepatocellular carcinoma, while a single marker (Piwil2/
Piwil4) cannot be used for prognosis judgment. PIWIL3 and PIWIL4 were currently showed prognostic relevance in breast cancer [93]. These observations provide potential importance 
of PIWI proteins in tumorigenesis. Nevertheless, how piRNAs interact with PIWI proteins to participate in tumorigenesis, invasion and metastasis needs further elucidation.
piRNAs and PIWI interactions in cancerAlthough there are many studies reported on the expression pattern of piRNAs or PIWI 
proteins in tumorigenesis, few studies have investigated on the role of piRNAs interacting 
with PIWI proteins. It remains unclear whether PIWI proteins regulate cancer cell proliferation, apoptosis, metastasis and invasion in the cytoplasm independently or PIWI 
proteins perform epigenetic control of homeostasis by taken to the nucleus with piRNAs. 
Therefore, it takes scientists’ effort to continue exploring underlying mechanisms between piRNAs and PIWI proteins in piRNA-related diseases.
Therapeutic insights into piRNAs and PIWI proteinsAt present, there are several therapeutic methods designed according the characteristics 
of piRNAs (Fig. 3). The most appealing is the synthetic piRNAs which could block the synthesis 
of cancer related proteins by binding to mRNAs. Different from miRNAs, which need to be processed by enzymes and regulate several mRNAs [124], piRNAs have the advantage of not 
requiring enzymes processing and better specificity to targets. PIWI antibodies are another 
kind of speculative approach that could affect cancer proliferation clinically. Besides, it could be regarded as a post-translational approach in combinatory therapies for diverse cancers 
[125]. Actually, blocking the harmful component production may be better than antagonizing the undesired effects of an already functional molecule. Therefore, transcriptional silencing is an attractive direction and piRNAs are appropriate for its role in transcriptional silencing. 
Specific synthetic piRNAs are designed to bind PIWI proteins and exert genomic silencing 
on PIWI genes at transcriptional level. The cancer/testis antigens (CTAs) is a kind of tumor 
antigens and specifically expressed in normal testicular tissue, PIWI proteins could be 
a kind of CTAs because of its restrictive expression and function in tumorogenesis. Thus, another strategy is focus on the PIWI proteins. Reverse to the conventional ‘ping-pong’ mechanism of piRNA biogenesis that provide additional piRNAs to cause self-enhancement, 
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it inversely blocked the production of the PIWI protein [35, 126]. Previous studies have 
already demonstrated that the expression of PIWI proteins were negatively correlated with 
patients’ survival, and inhibition of PIWI proteins could reduce the number of G2/M phase cells and enhance the expression of p53 protein, thus inhibiting proliferation and promoting apoptosis [105, 111]. In addition, PIWI proteins can increase the resistance to chemotherapy 
drugs such as cisplatin, which is widely used to treat malignancies but has the limitation of dose-dependent nephrotoxicity [127]. Thus, decrease of the PIWI proteins expression could increase the sensitivity of cancer cells to cisplatin (CDDP), providing potential strategies 
to overcome chemoresistance for patients who receive chemotherapy [128]. For example, 
Wang et al. [129] recently identified the up-regulated PIWI-interacting RNA likes (piR-Ls) piR-L-138 upon chemoresistance to CDDP-based chemotherapy in lung squamous cell 
carcinoma (LSCC) and confirmed the enhanced sensitivity of LSCC to agents by targeting the up-regulated piR-L-138 both in vitro and in vivo.In clinical treatment, the application of all there therapeutic strategies could be utilized 
in combination to make full use of each method; For instance, to decrease the side effects of conventional cytotoxic drugs and to improve the response to therapy, PIWI antibodies 
could be adopted to deliver drugs to cancer cells, which has been used in other antibodies as a delivery strategy [125]. Though the investigations of therapeutic methods on piRNAs are 
still on the initial stage, more and more therapeutic methods will be put into use with the understanding of the mechanisms and functions of piRNAs in cancer reinforced in the near future.
piRNAs dataset and predictions
The Indian scientists Sai Lakshmi S et al. [130] established the first piRNA database-
piRNABank, to save the new discovered piRNA sequences. piRNABank is a highly user-
friendly resource which stores nearly 20 million empirically known sequences and other related information on piRNAs reported in human, mouse and rat. The database supports 
organism and chromosome-wise comprehensive search features including accession numbers, localization on chromosomes, gene name or symbol, sequence homology-based search, clusters and corresponding genes and repeat elements. It also displays each piRNA 
or piRNA cluster on a graphical genome-wide map (http://pirnabank.ibab.ac.in/). These 
databases make us better investigate and understand circRNAs and their association with diseases.In addition to piRNA datasets, some studies have dedicated to analyze computational 
identification of piRNAs over the past few years. Betel et al. [131] trained a Support Vector 
Machine (SVM) classifier to distinguish between 5’-RNA and all other uridin positions for 
mouse piRNA sequences with a precision of 61–72 percent. But their method could not 
predict piRNA derived from the 3’-UTR of mRNA effectively which are produced by Ping 
Pong model. Zhang et al. [132] used Fisher separator algorithm by setting different cutoffs 
Fig. 3. Cancer therapy via targeting piRNAs and PIWI proteins. Synthetic 
piRNAs could block the synthesis of cancer related proteins by binding to mRNAs in transcriptional and posttranscriptional methods. PIWI antibodies could affect cancer proliferation clinically at the post-translational level. The “piRNAi” are designed to bind PIWI proteins and exert genomic silencing on PIWI genes 
at transcriptional level when targeting 
DNA, while designed to contain specific 
sequence to be associated with proteins 
of the Argonaute family when targeting mRNA.
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for piRNA identification in five model species including mice, humans, rats, fruit fly, and 
nematode with a precision of over 90% and a sensitivity of over 60%. Brayet et al. [133] 
integrated machine learning method based on multiple kernels and SVM classifier to identify the human and Drosophila piRNAs. Wang et al. [134] performed transposon interaction and 
a SVM for piRNAs prediction to predict human, mouse and rat piRNAs with 90.6% accuracy. 
Seyeddokht et al. [135] proposed a prediction method to identify piRNA in human and 48 heterogeneous features (sequence and structural features). This novel method reached 
the accuracy of 99% on the benchmark dataset and revealed that the structural features are the most contributing features in piRNA prediction. Liu et al. [136] proposed a piRNA 
detection method based on sequence features including weighted k-mer, weighted k-mer 
with wildcards, position-specific base, and piRNA length. The piRNA sequences from human, 
mouse, rat, and drosophila were respectively used in this experiment. Compared to existing 
algorithms, the proposed method provided a better balance between precision and sensitivity 
(both are approximately 90%). Although the precision and sensitivity were slightly slower 
than previous piRNA prediction approaches, this proposed method was four-fold faster than 
piRPred and 229-fold faster than piRNA predictor. Generally, the effectiveness of piRNA detection tools still requires improvement.
Conclusion
piRNAs were first recognized more than a decade ago and are coming into attention 
with the development of high-throughput sequencing technologies and bioinformatics methods, especially their gene regulatory function both in the nucleus and in the cytoplasm. 
Nevertheless, there is still lack of a complete and clear understanding of the functions and interactions of piRNAs and PIWI proteins. Therefore, the complicated biogenesis and functions of piRNAs need further elucidation to improve our understanding of them in diverse diseases. At present, piRNA has been recognized to express aberrantly in a cancer-
specific manner, though there remain a majority of piRNAs to be investigated and specific molecular mechanisms to be explored. Despite many studies presented the aberrant expression pattern of piRNAs or PIWI proteins in cancer development, it remains unclear 
whether PIWI proteins regulate cancer cell proliferation, apoptosis, metastasis and invasion in the cytoplasm independently or PIWI proteins perform epigenetic control of homeostasis 
by taken to the nucleus with piRNAs. Discovering potential interactions may lead to novel 
discoveries of malignancy-associated pathways affected by altered piRNA expressions. 
Therefore, it would be possible to decipher underlying molecular functions that influence piRNA dysregulation in tumorogenesis by further understanding physiological functions. 
Furthermore, the available functions would deepen our understanding on therapeutic 
methods of piRNA in cancer. In the future, with scientists’ endeavors and applications of 
new methods, many more piRNAs will be well identified and the mechanistic role of piRNA in tumour progression is sure to provide novel insight into the implication in cancer study.
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